Zoetis Q3 FY26: where the revenue came from and where it went
The whole income statement of Zoetis for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2026
- Reported
- Nov 5, 2026
Revenue$2.39B
+0% year over year
Gross profit$1.69B
71% margin
Operating profit$0.80B
34% margin
Net profit$0.59B
25% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 2.39 | 100% | +0% |
| Parasiticides | 0.58 | 24% | |
| Vaccines | 0.54 | 23% | |
| Other revenue | 0.38 | 16% | |
| Anti infective products | 0.28 | 12% | |
| Pain sedation | 0.20 | 8% | |
| Other pharmaceuticals | 0.17 | 7% | |
| Animal health diagnostics | 0.13 | 5% | |
| Swine | 0.12 | 5% | |
| Cost of revenue | −0.70 | 29% | |
| Gross profit | 1.69 | 71% margin | |
| SG&A | −0.58 | 24% | +0pp |
| Other | −0.31 | 13% | |
| Operating profit | 0.80 | 34% margin | −3pp |
| Interest & other costs | −0.07 | ||
| Tax | −0.14 | ||
| Net profit | 0.59 | 25% margin | −5pp |
11 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest